As we age, the risk of developing neurological disorders, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis (MS), increases. These diseases can be debilitating and, in some cases, fatal.
They are also difficult to treat because they involve complex mechanisms that are not yet fully understood. However, recent research suggests that a group of compounds called specialized pro-resolving mediators (SPMs) may have therapeutic potential in reducing neuro-inflammation and improving brain health.
Neuro-inflammation is a common feature of many neurological diseases, and it occurs when the immune system is activated in response to a threat to the brain. While neuro-inflammation is a natural process that helps to protect the brain from injury and infection, it can also be harmful if it becomes chronic or excessive. Chronic neuro-inflammation is thought to contribute to the development and progression of many neurological diseases.
SPMs are a group of bioactive lipids that are derived from omega-3 fatty acids. They are involved in the resolution of inflammation, which means that they help to bring the immune response back to its normal state after an infection or injury. SPMs are produced in the body in response to inflammation, and they act by suppressing the production of pro-inflammatory molecules and promoting the clearance of inflammatory cells.
Several studies have investigated the potential of SPMs in reducing neuro-inflammation and improving brain health. For example, a study published in the Journal of Neuroinflammation found that SPMs reduced the severity of inflammation in a mouse model of MS. Another study published in the Journal of Alzheimer's Disease found that SPMs improved cognitive function in a mouse model of Alzheimer's disease.
In my experience, the use of SPMs in clinical practice has been promising. I have seen several patients with neurological diseases, such as MS and Parkinson's disease, who have experienced significant improvements in their symptoms after taking SPMs. While these anecdotal reports are not conclusive, they suggest that SPMs may have therapeutic potential in reducing neuro-inflammation and improving brain health.
The mechanism of action of SPMs in reducing neuro-inflammation is not yet fully understood. However, it is thought that SPMs act by inhibiting the production of pro-inflammatory molecules, such as cytokines and chemokines, and promoting the clearance of inflammatory cells, such as microglia and astrocytes. This leads to a reduction in neuro-inflammation and an improvement in brain health.
One of the challenges in using SPMs in clinical practice is the lack of standardized dosing and formulation. SPMs are currently available as dietary supplements, and their potency and purity can vary widely between products. In addition, there is a lack of consensus on the optimal dose and duration of treatment for neurological diseases.
Despite these challenges, I believe that SPMs hold great promise in the treatment of neurological diseases. They are a natural and safe alternative to traditional anti-inflammatory drugs, which can have significant side effects. In addition, SPMs have been shown to have a broad range of therapeutic effects, including reducing pain, improving wound healing, and promoting tissue repair.
In conclusion, SPMs may have therapeutic potential in reducing neuro-inflammation and improving brain health. While further research is needed to fully understand the mechanism of action and optimal dosing and formulation, the use of SPMs in clinical practice has been promising. As a healthcare practitioner, I am excited about the potential of SPMs in the treatment of neurological diseases, and I look forward to seeing more research in this area in the future.
References:
1. Serhan CN & Chiang N. Specialised pro-resolving mediator network: an update on production and actions. Essays Biochem. 2020 Sep 23; 64(3): 443-462
2. Nathan C & Ding A. Nonresolving inflammation. Cell, 2010 Mar 19; 140(6): 871-82
3. Serhan CN & Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005 Dec;6(12): 1191-7
4. Subhramanyam CS, Wang C, et al. Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin Cell Dev Biol.2019 Oct; 94: 112-120
5. Soledad Cepeda, M, Stang P et al. (2016) Depression is associated with high levels of C-Reactive Protein and low levels of fractionated exhaled nitric oxide: results from the 2007-2012 National Health and Nutrition Examination Surveys. J Clin Psychiatry.1666-71.
6. Madison A, Andridge R, et al. Endotoxemia coupled with heightened inflammation predicts future depressive symptoms. Psychoneuroendocrinology. 2020 Dec; 122: 104864.
7. Bettcher BM, Kramer JH. longitudibal inflammation, cognitive decline, and Alzheimer’s disease: a mini-review. Clin Pharmacol Ther. 2014 Oct; 96(4): 464-9
8. Chitnis T, Weiner HL. CNS inflammation and neurodegeneration. J Clin Invest. 2017 Oct 2; 127 (10): 3577-3587. ;
9. Subhramanyam CS, Wang C, et al. Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin Cell Dev Biol.2019 Oct; 94: 112-120
10. Sparkman NL & Johnson RW. Neuroinflammation associated with ageing sensitises the brain to the effects of infection or stress. Neuroimmunomodulation. 2008: 15(4-6): 323-330.
11. Serhan CN. Discovery of specialised pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med. 2017 December; 58: 1-11.
12. Spite, M et al. Resolvins, specialised proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab, 2014 Jan 7;19(1): p.21-36
13. Recchiuti, A. Immunoresolving lipid mediators and resolution of inflammation in aging. Gerontol Geriat Res, 2014. 3: 151
14. Serhan CN & Chiang N. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol, 2013 13(4): p. 632-40
15. Serhan CN & Savill J. Resolution of inflammation: the beginning programs the end. Nature Immunol. 2005; 6:1191–1197.
16. Ponce J, Ulu A, et al. Role of specialized Pro-resolving mediators in reducing neuroinflammation in neurodegenerative disorders. Front AgingNeurosci. 2022; 14: 780811
17. Wang X, Zhu M, et al. Resolution of inflammation is altered in Alzheimer’s disease. The Journal of the Alzheimer’s Association. 14 February 2014.
18. Zhu M, Wang X, et al. Pro-resolving lipid mediators improve neuronal survival and increase AB42 phagocytosis. Mol Neurobiol.2016 May; 53(4): 2733-49.
19. Kantarci A, Aytan N, et al. Combined administration of resolving E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer’s disease. Exp Neurol. 2018 Feb; 300: 111-120.
20. Wu J, Wang A, et al. Lipoxin A4 inhibits the production of proinflammatory cytokines induced by B-amyloid in vitro and in vivo. Biochemical and Biophysical Research Communications. Volume 408, Issue 3, 13 May 2011, pages 382-387
21. Tian Y, Zhang Y, et al. Resolvin D2 recovers neural injury by suppressing inflammatory mediators expression in lipopolysaccharide-induced Parkinson’s disease rat model. Biochemical and Biophysical Research Communications. Volume 460, Issue 3, 8 May 2015, pages 799-805.
22. Yang T, Xu G, et al. Maresin 1 attenuates neuroinflammation in a mouse model of perioperative disorders. British Journal of Anaesthesia Volume 122, Issue 3, March 2019, pages 350-360.
23. Terrando N, Gomez-Galan M, et al. Aspirin-triggered resolving D1 prevents surgery-induced cognitive decline. The Faseb Journal. 24 May 2013
24. Luo CL, Li QQ, et al. Lipoxin A4 attenuates brain damage and downregulates the production of pro-inflammatory cytokines and phosphorylated mitogen-activated protein kinases in a mouse model of traumatic brain injury. Brain Research Volume 1502, 28 March 2013, Pages 1-10.
25. Bisicchia E, Sasso V, et al. Resolvin D1 halts remote neuroinflammation and improves functional recovery after focal brain damage via ALX/FPR2 receptor-regulated MicroRNAs. Mol Neurobiol. 2018 Aug; 55(8): 6894-6905.
26. Francos-Quijorna I, Santos-Nogueira E, et al. Maresin 1 promotes inflammatory resolution, neuroprotection, and functional neurological recovery after spinal cord injury. The Journal of Neuroscience. 29 November 2017, 37 (48) 11731-11743
Comments